Stockreport

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics, Inc.  (IKT) 
PDF BOSTON and ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company [Read more]